[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-disease-cad-eg-angina-myocardial-infarction-and-atherosclerotic-heart-disease-ashd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-disease-cad-eg-angina-myocardial-infarction-and-atherosclerotic-heart-disease-ashd":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,74,103,127,152,179,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100389155","registry-of-long-term-antithrombotic-therapy-1-100389155",false,"NCT04347200","REGistry of Long-term AnTithrombotic TherApy-1","Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes","REGATTA-1","Inclusion Criteria:\n\n* coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of CAD on imaging\n\nExclusion Criteria:\n\n* Subjects who are unwilling or unable to provide informed consent.\n* Acute coronary syndrome within 12 months before inclusion\n* Severe chronic heart failure (NYHA IV)\n* Stroke within 6 months before inclusion\n* Severe liver or muscle disease\n* Severe kidney disease \u002F renal failure with creatinine \\> 3 mg\u002Fdl\n* Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention -","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","5 Years","OBSERVATIONAL","To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes",[26,27],"Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))","Peripheral Artery Disease",[29],"Coronary Artery Disease, Peripheral Artery Disease","RECRUITING","2026-04-27",{"date":33,"type":34},"2026-05-01","ACTUAL",{"date":36,"type":34},"2015-01-15",{"date":38,"type":21},"2026-12-31",{"name":40,"class":41},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100602940","hybrid-exercise-program-for-heart-disease-effect-on-health-and-quality-of-life-100602940","NCT07130045","Hybrid Exercise Program for Heart Disease: Effect on Health and Quality of Life","Effect of Hybrid Endurance and Strength Training (HyBEST) on Health-Related Outcomes and Quality of Life in Patients With Coronary Artery Disease During Phase II Cardiac Rehabilitation Program","Inclusion Criteria:\n\n* Age of 18 years or older.\n* Diagnosed with coronary artery disease (CAD), with or without invasive treatment, maintaining a normal sinus rhythm and preserved left ventricular ejection fraction (LVEF).\n* In a stable clinical condition.\n* capable of regularly attending a supervised exercise program.\n* Able to complete questionnaires in English or Malay.\n\nExclusion Criteria:\n\n* They exhibited abnormal responses during the initial exercise test, such as irregular haemodynamic responses, ST segment depression greater than 2 mm, or any ventricular fibrillation.\n* Their forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) is less than 50% of the predicted value.\n* They cannot participate in exercise testing due to non-cardiac limitations.\n* They have been hospitalized due to heart failure within the past year.\n* They have uncontrollable hypertension.","75 Years",{"count":52,"type":21},84,"INTERVENTIONAL",[55],"NA","Cardiac rehabilitation (CR) participation remains suboptimal, partly due to logistical challenges and limited access to center-based programs. Hybrid Endurance-Strength Training (HybEST) offers an alternative model by combining supervised endurance and strength exercises with home-based components. The main questions it aims to answer are:\n\n* Does a hybrid exercise program significantly improve a patient's body function and structures \\[exercise capacity, body composition, and muscle strength\\] compared to usual care?\n* Does a hybrid exercise program significantly improve a patient's activity \\[functional capacity, physical activity, and total energy expenditure\\] compared to usual care?\n* Does a hybrid exercise program significantly improve a patient's participation \\[health-related quality of life\\] compared to usual care?\n\nThis single-center, two-arm parallel randomized clinical trial aims to evaluate the effects of HybEST on health-related outcomes and quality of life among patients with coronary artery disease in Phase II CR. Eligible participants will be randomly assigned in a 1:1 ratio to either the HybEST intervention group or the standard CR control group using a lottery method, specifically the sealed envelope approach. Assessments will be conducted at baseline (T0), Week 5 (T2), and Week 9 (T3) to measure changes in health-related outcomes and quality of life.",[26],[59,60,61,62],"coronary artery disease","combined training","hybrid","cardiac rehabilitation","NOT_YET_RECRUITING","2026-04-13",{"date":66,"type":34},"2026-04-17",{"date":68,"type":21},"2026-10",{"date":70,"type":21},"2027-12",{"name":72,"class":73},"University of Malaya","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":42},"100632249","angiography-derived-physiological-indices-for-outcome-prediction-in-patients-undergoing-oct-guided-pci-100632249","NCT07511231","Angiography-Derived Physiological Indices for Outcome Prediction in Patients Undergoing OCT-Guided PCI","Prognostic Value of Angiography-Derived Physiological Indices in Patients Undergoing OCT-Guided Percutaneous Coronary Intervention","ADOPT-PCI","Inclusion Criteria:-1.Age \\>= 18 years and \\\u003C 85 years. 2.Successful stent implantation under OCT guidance. 3.Availability of at least two optimal post-PCI angiographic projections separated by \\> 25 degrees and suitable for angiography-derived physiological analysis.\n\n\\-\n\nExclusion Criteria:1.PCI of the culprit vessel for ST-segment elevation myocardial infarction (STEMI).\n\n2.Cardiogenic shock or requirement for mechanical circulatory support. 3.Life expectancy of less than 1 year. 4.History of coronary artery bypass grafting (CABG). 5.Balloon angioplasty without stent implantation. 6.Severe procedural complications, including intraprocedural death, emergency CABG, or coronary perforation.\n\n7.Target-vessel diameter \\\u003C 2.5 mm. 8.Heart failure with New York Heart Association (NYHA) class III-IV symptoms or left ventricular ejection fraction (LVEF) \\\u003C 30%.\n\n\\-","84 Years",{"count":84,"type":21},1800,"The primary design of this study is an ambispective observational cohort study. In patients undergoing successful optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) with post-procedural angiographic images suitable for computational analysis, this study aims to evaluate the prognostic value of post-PCI angiography-derived physiological indices, specifically angiography-derived fractional flow reserve (Angio-FFR) and angiography-derived index of microcirculatory resistance (Angio-IMR), beyond conventional clinical risk factors and OCT-derived anatomical parameters. Specifically, the objectives are:\n\n1. To determine the associations of post-PCI Angio-FFR and Angio-IMR with the risk of Major Adverse Cardiovascular Events (MACE) during follow-up.\n2. To evaluate the incremental prognostic value of post-PCI Angio-FFR and Angio-IMR when added to models incorporating baseline clinical characteristics and OCT-derived anatomical parameters for predicting MACE.\n3. To assess whether the combined evaluation of Angio-FFR and Angio-IMR improves identification of residual risk after anatomically optimized, OCT-guided PCI.",[26],[88,89,90,91,92,93],"Optical Coherence Tomography","OCT-guided PCI","Angiography-derived Fractional Flow Reserve","Angiography-derived Index of Microcirculatory Resistance","Pullback Pressure Gradient","Major Adverse Cardiovascular Events","2026-03-30",{"date":96,"type":34},"2026-04-06",{"date":98,"type":21},"2026-04",{"date":100,"type":21},"2029-07",{"name":102,"class":73},"Beijing Anzhen Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100627499","a-privacy-preserving-ocr-llm-system-for-coronary-syndrome-subtyping-from-admission-hpi-multicenter-validation-in-china-and-the-us-100627499","NCT07449429","A Privacy-Preserving OCR-LLM System for Coronary Syndrome Subtyping From Admission HPI: Multicenter Validation in China and the US","Development and Multicenter Validation of a Privacy-Preserving OCR-LLM Pipeline for Four-Subtype Coronary Syndrome Classification Using Admission HPI Across Heterogeneous EHR Systems","OCR-LLM-CHD","Inclusion Criteria:Hospital encounters with admission HPI documenting sym\n\n2a4afaef-9dc1-47fc-874f-9dffaf7…\n\nevant to coronary syndrome subtyping.\n\nCases with sufficient documentation to assign one of four target subtypes (STEMI, NSTEMI, UA, CCS) by adjudication.\n\n\\-\n\nExclusion Criteria: Unclear subtype or incomplete\u002Funcertain time information preventing gold standard assignment.\n\nNon-CHD primary reason for admission after screening (for MIMIC-IV cohort).\n\n\\-",{"count":112,"type":21},10,"This study develops and validates a privacy-preserving OCR-LLM pipeline that converts admission history of present illness (HPI) records into structured coronary syndrome subtypes (STEMI, NSTEMI, unstable angina, and chronic coronary syndrome). The system first extracts text from de-identified HPI images using locally deployed OCR, then applies large language models with a fixed diagnostic prompt to generate subtype classification and evidence. Performance is evaluated in an internal validation cohort and multiple external datasets covering heterogeneous EHR templates, emergency department cases, and an English dataset from MIMIC-IV. A clinician usability study assesses changes in diagnostic accuracy and time with and without tool assistance.",[26,115,116,117],"Acute Coronary Syndromes","ST-segment Elevation Myocardial Infarction (STEMI)","Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)","2026-02-27",{"date":120,"type":34},"2026-03-04",{"date":122,"type":21},"2026-02-28",{"date":124,"type":21},"2026-03-08",{"name":126,"class":41},"China National Center for Cardiovascular Diseases",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":137,"studyType":23,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":42},"100620141","coronary-imaging-and-metabolic-indicators-based-risk-prediction-model-for-coronary-artery-diseasecmi-riskcad-100620141","NCT07353762","Coronary Imaging and Metabolic Indicators-Based Risk Prediction Model for Coronary Artery Disease(CMI-RiskCAD)","Coronary Imaging and Metabolic Indicators-Based Risk Prediction Model for Coronary Artery Disease:A Retrospective and Prospective Cohort Study","CMI-RiskCAD","Inclusion Criteria:\n\n(1)Completion of CCTA examination. (2)Age ≥ 18 years. (3)Signed written informed consent, and willing and able to comply with baseline assessment and long-term follow-up.\n\nExclusion Criteria:\n\n1. Acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) occurring within 72 hours; history of coronary artery bypass grafting (CABG); severe valvular heart disease; dilated or hypertrophic cardiomyopathy; congenital heart disease; or heart failure (NYHA functional class III-IV).\n2. Severe hepatic insufficiency (Child-Pugh class C) or renal failure (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n3. Pregnancy or lactation.\n4. Life expectancy of less than 1 year, or any other condition that, in the opinion of the investigator, renders the patient unsuitable for participation in the study.",{"count":136,"type":21},10960,"60 Months","The primary design of this study is an ambispective cohort study. We plan to integrate coronary imaging features (including parameters derived from Coronary Computed Tomography Angiography(CCTA) and coronary angiography(CAG)), coronary functional indices (e.g., FFR, QFR), and metabolic biomarkers (e.g., LDL-C, Lp(a), hs-CRP). First, we will develop a multimodal risk prediction model for coronary artery disease using a retrospective cohort; subsequently, we will validate the model in a prospective cohort to assess its performance in discriminating high- versus low-risk individuals and to explore its potential clinical utility for risk stratification and decision-making.",[26],[141,142,143],"Coronary Computed Tomography Angiography","Perivascular Fat Attenuation Index","Coronary Angiography-derived FFR","2026-01-18",{"date":146,"type":34},"2026-01-20",{"date":148,"type":21},"2026-01-01",{"date":150,"type":21},"2035-12-31",{"name":102,"class":73},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":162,"studyType":23,"phases":4,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":178},"100607833","barriers-limiting-oct-penetration-in-clinical-practice-100607833","NCT07193693","Barriers Limiting OCT Penetration in Clinical Practice","Assessment of Barriers Limiting Optical Coherence Tomography Penetration in Actual Clinical Practice & Training (OCT2ACT) Study","OCT2ACT","1. Cohort intracoronary imaging NO\n\n   • Inclusion criteria\n\n   Patients undergoing clinically indicated PCI and having at least one of the following criteria (suggestive for complex PCI) without receiving intracoronary imaging:\n   * Long lesion (\\>38 mm)\n   * True bifurcation involving side-branch with a reference diameter of \\>2.5 mm and Medina 1.1.1\n   * Left main bifurcation\n\n     • Exclusion criteria\n   * Refusal of informed consent\n2. Cohort intracoronary imaging YES according to guidelines recommendation\n\n   • Inclusion criteria\n\n   Patients undergoing clinically indicated PCI with the guidance of intracoronary imaging (OCT or IVUS) and having at least one of the following criteria (suggestive for complex PCI) receiving imaging:\n   * Long lesion (\\>38 mm)\n   * True bifurcation involving side-branch with a reference diameter of \\>2.5 mm and Medina 1.1.1\n   * Left main bifurcation\n\n     • Exclusion criteria\n   * Refusal of informed consent\n3. Cohort intracoronary imaging YES outside guidelines recommendation\n\n   * Inclusion criteria Patients undergoing IVUS or OCT use.\n   * Exclusion criteria\n\n     * Long lesion (\\>38 mm)\n     * True bifurcation involving side-branch with a reference diameter of \\>2.5 mm and Medina 1.1.1\n     * Left main bifurcation\n     * Refusal of informed consent",{"count":161,"type":21},1000,"1 Day","The updated guidelines from the European Society of Cardiology (ESC) for chronic coronary syndrome (CCS) have upgraded the use of IVUS and OCT to a class IA recommendation for complex PCI, based on evidence showing a reduction in serious clinical events, including mortality, compared to conventional angiography alone. Despite this, IVUS and OCT are underutilized in daily practice due to factors such as time, cost, and limited technology availability. Investigating the reasons behind this underuse is necessary, especially now that these technologies are more accessible and cost-effective. Additionally, OCT could be particularly helpful in specific cases such as coronary bifurcations and severe calcifications, warranting further evaluation of its use in these settings.\n\nThe objective of the study OCT2ACT is to investigate:\n\n* The main reasons\u002Fbarriers limiting the use of intracoronary imaging in complex PCI cases where it is indicated as suggested by guidelines;\n* The main reasons behind the selection of IVUS or OCT in such patients;\n* In cases where OCT is used, how this technology can influence the procedural planning and optimization in complex clinical settings.\n\nThe participating centers will include three cohorts of patients:\n\n1. Cohort intracoronary imaging NO: patients who meet the inclusion\u002Fexclusion criteria, but did not undergo intracoronary imaging (IVUS or OCT) due to operator's decision.\n\n   The aim is to describe the main reasons\u002Fbarriers for not using imaging.\n2. Cohort intracoronary imaging YES according to guidelines recommendation: patients who meet the inclusion\u002Fexclusion criteria and underwent intracoronary imaging as recommended by guidelines.\n\n   The aim is to understand the main reasons for the decision to use IVUS or OCT and the clinical benefits perceived by the operator.\n3. Cohort intracoronary imaging YES outside guidelines recommendation: patients who meet the inclusion\u002Fexclusion criteria and underwent intracoronary imaging (IVUS or OCT) outside.",[26],[166,167,168],"IVUS","OCT","PCI","2026-01-05",{"date":171,"type":34},"2026-01-06",{"date":173,"type":34},"2025-09-15",{"date":175,"type":21},"2026-05-15",{"name":177,"class":73},"Consorzio Futuro in Ricerca",2,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":185,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":42},"100573237","development-of-a-novel-risk-prediction-tool-for-emergency-department-patients-symptoms-of-coronary-artery-disease-100573237","NCT06743672","Development of a Novel Risk Prediction Tool for Emergency Department Patients Symptoms of Coronary Artery Disease","Inclusion Criteria:\n\n1. Symptoms of chest pain or of suspected cardiac ischemia;\n2. Age 25 or older;\n\nExclusion Criteria:\n\n1. Diagnosis of Myocardial Infarction in the Emergency Department; OR Maximal high-sensitivity cardiac troponin concentration 115 ng\u002FL or Higher; OR Change between serial samples of high-sensitivity troponin \\>3ng\u002FL AND \\>30% of initial concentration.\n2. Acute ischemic ECG changes (ST segment elevation or depression, new T-wave inversion, New left bundle branch block; Wellen's\u002FDeWinter T waves);\n3. Alternative diagnosis identified in the ED (e.g. pneumonia, pulmonary embolism, aortic dissection, pancreatitis; peri\u002Fmyocarditis);\n4. Acute coronary syndrome or revascularization in previous 30 days;\n5. Expected lifespan \\\u003C 6 months per treating clinician.","25 Years",{"count":187,"type":21},6500,"Patients with chest pain and symptoms of acute coronary syndromes (ACS) account for over 600,000 emergency department (ED) visits annually in Canada. 85% of these patients do not have an ACS, and most are discharged from the ED after a thorough evaluation. However, a large proportion of these patients (approximately 180,000 annually) are referred for outpatient objective cardiac testing (exercise stress tests, myocardial perfusion scans, coronary CT angiography) after ED discharge, even though their short-term risk of major adverse cardiac events such as death, new myocardial infarction or need for revascularization is very small. This contributes to substantial low-value healthcare utilization, and limits access for those patients who are likely to benefit from objective testing.\n\nClinical risk prediction tools can improve the appropriateness of utilization of cardiac testing. However, existing risk prediction tools were developed prior to the advent of new high-sensitivity cardiac troponin assays, were derived in non-representative populations and, when applied to ED patients with low cardiac troponin concentrations, systematically overestimate short-term risk of major adverse cardiac events (MACE).\n\nNew, more specific, risk prediction tools are required to accurately guide clinical decision-making for patients who have had an emergency department evaluation for suspected coronary disease. The objective of this research program is to develop individualized risk prediction tools for patients who have had an MI ruled out in the emergency department, to identify patients who are likely to benefit from additional cardiac testing, and to guide the appropriate timing of testing. In other words, the objective is to provide personalized risk estimates to get the Right Patient the Right Test at the Right Time.\n\nWe will conduct a multicenter prospective cohort study including emergency department chest pain patients to derive personalized risk prediction tools to distinguish patients at low risk of MACE and not requiring additional cardiac testing from patients who are likely to benefit from additional cardiac testing. We will leverage the existing clinical research infrastructure of the Canadian Emergency Department Rapid Response Network to enrol a large population of representative patients.\n\nThe risk prediction tools that we will develop will innovate in the following ways:\n\n1. We will include the right population, namely patients who have had MI ruled out in the ED, as current risk prediction tools were derived in different populations;\n2. We will provide improved accounting for sex and the presence of pre-existing coronary disease compared to previous tools;\n3. We will incorporate the latest generation cardiac troponin assay;\n4. We will investigate the utility of other commonly available biomarkers that have excellent predictive utility in other cardiovascular diseases;\n5. We will undertake time-to-event analyses to suggest the optimal timing of additional cardiac testing;\n\n5\\) We will provide granular, individualized risk estimates to guide decision-making around which patients need additional testing.\n\nThe knowledge product of this work will improve patient outcomes while also optimizing the appropriate utilization of objective cardiac testing modalities.",[26],[191,192,193],"Coronary artery disease","chest pain","Emergency Medicine","2025-05-28",{"date":196,"type":34},"2025-06-03",{"date":198,"type":21},"2025-06-15",{"date":200,"type":21},"2027-12-31",{"name":202,"class":73},"University of Calgary",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":53,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100591547","sirolimus-with-corticosteroid-therapy-for-rapid-recurrences-of-coronary-unexplained-in-stent-restenosis-100591547","NCT06981845","Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis","Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis (STOP-RECUR) Study","STOP-RECUR","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Able to understand the trial design and sign an informed consent form\n3. Patients meeting the RECUR definition\n4. Satisfactory results from revascularization within the past two weeks\n5. Receiving standard secondary prevention medication for coronary heart disease with treatment targets achieved\n\nExclusion Criteria:\n\nPregnant women, individuals known to be allergic to the study drug, those currently participating in other interventional clinical trials, or participants deemed unsuitable for this study based on the investigator's judgment.",{"count":212,"type":21},52,[55],"This study aims to evaluate, through a multicenter, prospective, double-blind, randomized, placebo-controlled clinical trial, whether immunosuppressive therapy improves target lesion-related cardiovascular outcomes compared to placebo treatment in patients with Rapid rEcurrence of Coronary Unexplained in-stent Restenosis (RECUR).",[216,26],"In-stent Restenosis Lesion","2025-05-13",{"date":219,"type":34},"2025-05-21",{"date":221,"type":21},"2025-06-01",{"date":223,"type":21},"2028-06-01",{"name":126,"class":41}]